Zobrazeno 1 - 10
of 630
pro vyhledávání: '"J Carl, Barrett"'
Autor:
Mingchao Xie, Miljenka Vuko, Jaime Rodriguez-Canales, Johannes Zimmermann, Markus Schick, Cathy O’Brien, Luis Paz-Ares, Jonathan W. Goldman, Marina Chiara Garassino, Carl M. Gay, John V. Heymach, Haiyi Jiang, J. Carl Barrett, Ross A. Stewart, Zhongwu Lai, Lauren A. Byers, Charles M. Rudin, Yashaswi Shrestha
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-17 (2024)
Abstract Background We explored potential predictive biomarkers of immunotherapy response in patients with extensive-stage small-cell lung cancer (ES-SCLC) treated with durvalumab (D) + tremelimumab (T) + etoposide-platinum (EP), D + EP, or EP in the
Externí odkaz:
https://doaj.org/article/dac90161c2bf43f78841723ad0ac6b3b
Autor:
Ansh Kapil, Andreas Spitzmüller, Nicolas Brieu, Susanne Haneder, Anatoliy Shumilov, Armin Meier, Fabiola Cecchi, Alice Barkell, Nathalie Harder, Katrin Mittermaier, Ana Hidalgo-Sastre, Regina Alleze, Markus Schick, Günter Schmidt, Hadassah Sade, Zenta Tsuchihashi, Fumitaka Suto, Mark Gustavson, J. Carl Barrett, Danielle Carroll
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Many targeted cancer therapies rely on biomarkers assessed by scoring of immunohistochemically (IHC)-stained tissue, which is subjective, semiquantitative, and does not account for expression heterogeneity. We describe an image analysis-base
Externí odkaz:
https://doaj.org/article/b0bb13ca3be44be6a20f420d905211e6
Autor:
Charlie Garnett-Benson, Sarah Warren, Anne Monette, Alexandra Snyder, Janis M Taube, J Carl Barrett, Kurt A Schalper, Brian Topp
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Therapies targeting the programmed cell death protein-1/programmed death-ligand 1 (PD-L1) (abbreviated as PD-(L)1) axis are a significant advancement in the treatment of many tumor types. However, many patients receiving these agents fail to respond
Externí odkaz:
https://doaj.org/article/01ae6040ff4e401b8cab10bfcad5a0ee
Autor:
Elizabeth L. Hardaker, Emilio Sanseviero, Ankur Karmokar, Devon Taylor, Marta Milo, Chrysis Michaloglou, Adina Hughes, Mimi Mai, Matthew King, Anisha Solanki, Lukasz Magiera, Ricardo Miragaia, Gozde Kar, Nathan Standifer, Michael Surace, Shaan Gill, Alison Peter, Sara Talbot, Sehmus Tohumeken, Henderson Fryer, Ali Mostafa, Kathy Mulgrew, Carolyn Lam, Scott Hoffmann, Daniel Sutton, Larissa Carnevalli, Fernando J. Calero-Nieto, Gemma N. Jones, Andrew J. Pierce, Zena Wilson, David Campbell, Lynet Nyoni, Carla P. Martins, Tamara Baker, Gilberto Serrano de Almeida, Zainab Ramlaoui, Abdel Bidar, Benjamin Phillips, Joseph Boland, Sonia Iyer, J. Carl Barrett, Arsene-Bienvenu Loembé, Serge Y. Fuchs, Umamaheswar Duvvuri, Pei-Jen Lou, Melonie A. Nance, Carlos Alberto Gomez Roca, Elaine Cadogan, Susan E. Critichlow, Steven Fawell, Mark Cobbold, Emma Dean, Viia Valge-Archer, Alan Lau, Dmitry I. Gabrilovich, Simon T. Barry
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Abstract The Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical benefit in melanoma and lung cancer patients who progressed on immunotherapy. Here we
Externí odkaz:
https://doaj.org/article/189773f2417346dcbdf8b6281d57effa
Autor:
Rakesh Kumar, Keunchil Park, Frances A Shepherd, John V Heymach, Quincy Chu, Sylvia Hartl, J Carl Barrett, Sonia Iyer, Parneet Cheema, Marianna Koczywas, Maximilian Hochmair, Giuseppe Galletti, Mark Gustavson, Brent Evans, Jan Cosaert
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/fc6c2d7f62824e51983bea009bbe51ac
Autor:
Guenter Schmidt, Nicolas Brieu, Harald Hessel, Andreas Spitzmüller, Jaime Rodriguez Canales, Helen Angell, Markus Schick, Mingchao Xie, Mari Heininen-Brown, Miljenka Vuko, Monica Azqueta Gavaldon, Felix Segerer, Marco Testori, Michael Surace, Shashank Saran, Hadassah Sade, J Carl Barrett, Giulia Fabbri, Alma Andoni
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/7c5f992f1f3d413b93f89f92865f3373
Autor:
Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-9 (2023)
Abstract Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. In the Phase III FLAURA study (NCT02296125), first-line osimer
Externí odkaz:
https://doaj.org/article/44b83896764b4d85bc01ecb3c4630dd4
Autor:
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh S. Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A. Shepherd, Krishna C. Bulusu, Gianluca Laus, Barbara Collins, J. Carl Barrett, Ryan J. Hartmaier, Vassiliki Papadimitrakopoulou
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-8 (2023)
In the phase III AURA3 study (NCT02151981), the third-generation epidermal growth factor receptor tyrosine kinase inhibitor osimertinib prolonged progression-free survival versus platinum-doublet chemotherapy in patients with EGFR T790M advanced NSCL
Externí odkaz:
https://doaj.org/article/97023c9e42e0450eab3688b9d4689761
Autor:
Natalia Lukashchuk, Alan Barnicle, Carrie A. Adelman, Joshua Armenia, Jinyu Kang, J. Carl Barrett, Elizabeth A. Harrington
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Prostate cancer is among the most common diseases worldwide. Despite recent progress with treatments, patients with advanced prostate cancer have poor outcomes and there is a high unmet need in this population. Understanding molecular determinants un
Externí odkaz:
https://doaj.org/article/75ddc3fc85e340e5abec988d20c8dc6f
Autor:
Andi K. Cani, Emily M. Dolce, Elizabeth P. Darga, Kevin Hu, Chia‐Jen Liu, Jackie Pierce, Kieran Bradbury, Elaine Kilgour, Kimberly Aung, Gaia Schiavon, Danielle Carroll, T. Hedley Carr, Teresa Klinowska, Justin Lindemann, Gayle Marshall, Vicky Rowlands, Elizabeth A. Harrington, J. Carl Barrett, Nitharsan Sathiyayogan, Christopher Morrow, Valeria Sero, Anne C. Armstrong, Richard Baird, Erika Hamilton, Seock‐Ah Im, Komal Jhaveri, Manish R. Patel, Caroline Dive, Scott A. Tomlins, Aaron M. Udager, Daniel F. Hayes, Costanza Paoletti
Publikováno v:
Molecular Oncology, Vol 16, Iss 10, Pp 1969-1985 (2022)
Nearly all estrogen receptor (ER)‐positive (POS) metastatic breast cancers become refractory to endocrine (ET) and other therapies, leading to lethal disease presumably due to evolving genomic alterations. Timely monitoring of the molecular events
Externí odkaz:
https://doaj.org/article/3982ed92674c47fd83894acff6f5a9d3